TYME continues to develop a strong pipeline of cancer metabolism-based therapies for advanced cancers. We are focusing on metastatic and hard-to-treat cancers for which current therapies are inadequate. We believe that targeting cancer’s metabolism by disrupting protein synthesis and increasing oxidative stress has advantages over existing treatment approaches and may benefit patient’s lives with improved efficacy and safety profile. Building on our growing knowledge of the biology behind cancer metabolism in solid and hematological cancers, we are investing in novel therapeutic approaches and discovering ways to attack the disease source through multiple mechanisms of actions, including inducing amino acid transport, disrupting critical protein synthesis, modulating autophagy and inhibiting key intracellular pathways.